Day: June 12, 2022

Bombardier to Resume Negotiations with IAMAW Local 712 Chapter Representing Workers in Dorval and Saint-Laurent, Québec

Bombardier to Resume Negotiations with IAMAW Local 712 Chapter Representing Workers in Dorval and Saint-Laurent, Québec

Written by Customer Service on . Posted in Public Companies.

MONTREAL, June 12, 2022 (GLOBE NEWSWIRE) — Bombardier is disappointed with the results of this weekend’s vote by IAMAW Local 712 members, who have not ratified an offer for the renewal of the collective bargaining agreement. Bombardier is examining options to determine next steps and has confirmed with IAMAW Local 712 that negotiations will resume on Tuesday, June 14. The company is confident it is on the right track and remains engaged toward a successful future for all employees, including IAMAW Local 712 members as well as the sites in the Montreal area where they work. Bombardier has a contingency plan that will be put in place at the affected sites to reduce the impact on operations during the IAMAW Local 712 planned study day set for Monday, June 13. About Bombardier Bombardier is a global leader in aviation, focused on designing,...

Continue reading

Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma

Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma

Written by Customer Service on . Posted in Public Companies.

Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib Topline results from the full FIREFLY-1 trial population expected in Q1 2023 Day One plans to initiate a pivotal Phase 3 clinical trial of tovorafenib in front-line pediatric low-grade glioma (pLGG), with first patient dosed expected in Q3 2022 Company to host conference call and webcast tomorrow, June 13, at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif., June 12, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced positive initial data from the first 22 Response Assessment for...

Continue reading

Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency

Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency

Written by Customer Service on . Posted in Public Companies.

Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1 Atlanta, Georgia (US), 12 June 2022 – Today, Novo Nordisk announced results of once-weekly Sogroya® (somapacitan) injection in helping children achieve growth targets of annualised height velocity (AHV).1 These phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented today at the Endocrine Society’s Annual Meeting (ENDO 2022) in Atlanta, Georgia (US). “The existing treatment options available for children with growth hormone deficiency require daily injections for many years,” said Dr. Bradley Miller, MD, PhD, Division of Pediatric Endocrinology, University of Minnesota Masonic Children’s Hospital. “Based on the results of...

Continue reading

Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL

Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL

Written by Customer Service on . Posted in Public Companies.

In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after five years1 Nearly half (49%) of those in remission stayed in remission after a median follow-up of 5.5 years, demonstrating the long-term benefit and curative potential of one-time Kymriah infusion1 The safety profile remains consistent with previously reported results, without late adverse effects in these heavily pretreated patients1 Novartis is committed to delivering transformative CAR-T cell therapies with these longer-term data, recent regulatory approvals for Kymriah in r/r follicular lymphoma and ongoing development of T-Charge™ platform Basel, June 12, 2022 — Novartis today announced long-term five-year follow-up results from the ELIANA...

Continue reading

Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL

Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL

Written by Customer Service on . Posted in Public Companies.

In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than five years1 44% of patients who experienced remission within three months of infusion were still in remission at the five-year mark, demonstrating the long-term benefit and curative potential of one-time Kymriah infusion1 The safety profile remains consistent with previously reported results, without late adverse effects in these heavily pretreated patients1 Novartis is committed to delivering transformative CAR-T cell therapies with these longer-term data, recent regulatory approvals for Kymriah in r/r follicular lymphoma and ongoing development of T-Charge™ platform Basel, June 12, 2022 — Novartis today announced long-term results...

Continue reading

Independent Contractor Fatality at Peace River Pulp Mill

Independent Contractor Fatality at Peace River Pulp Mill

Written by Customer Service on . Posted in Public Companies.

PEACE RIVER, Alberta, June 11, 2022 (GLOBE NEWSWIRE) — Mercer International Inc. (“Mercer” or the “Company”) (Nasdaq: MERC) is deeply saddened to announce that an independent contractor’s employee suffered a tragic and fatal workplace accident at our Peace River mill in Peace River, Alberta on June 11, 2022. Mercer has initiated an incident investigation and is fully cooperating with the authorities. “We are saddened about the loss of life of one of our contractor’s employees and our thoughts are with the individual’s family and colleagues. An investigation of the accident has been started and we are working with the authorities and the contracting company to find out how this tragic incident occurred,” stated Roger Ashfield, Managing Director of Mercer Peace River. “Mercer’s emergency procedures were immediately activated...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.